Marker Therapeutics, Inc. (MRKR) › Shares OutstandingMarker Therapeutics, Inc. (MRKR) — Shares OutstandingAnnual figures by period end, from SEC filings.2010-12-31: 40.26M2011-12-31: 52.07M2012-12-31: 764.0K2013-12-31: 1.47M2014-12-31: 20.32M2015-12-31: 5.88M2016-12-31: 8.40M2017-12-31: 10.60M2018-12-31: 45.40M2019-12-31: 45.70M2020-12-31: 50.70M2021-12-31: 8.30M2022-12-31: 8.40M2023-12-31: 8.90M2024-12-31: 10.70M2025-12-31: 16.70M16.70M2010-12-31Shares Outstanding (shares)2025-12-31Period endedShares OutstandingChange YoYSource filing2025-12-3116.70M+56.1%2026-03-18Balance as of period end2024-12-3110.70M+20.2%2026-03-18Balance as of period end2023-12-318.90M+6.0%2025-03-31Balance as of period end2022-12-318.40M+1.2%2024-03-26Balance as of period end2021-12-318.30M-83.6%2023-03-22Balance as of period end2020-12-3150.70M+10.9%2022-03-17Balance as of period end2019-12-3145.70M+0.7%2021-03-09Balance as of period end2018-12-3145.40M+328.3%2020-03-12Balance as of period end2017-12-3110.60M+26.2%2019-03-15Balance as of period end2016-12-318.40M+42.8%2018-03-23Balance as of period end2015-12-315.88M-71.0%2017-03-14Balance as of period end2014-12-3120.32M+1286.3%2016-04-14Balance as of period end2013-12-311.47M+91.8%2015-04-15Balance as of period end2012-12-31764.0K-98.5%2014-04-17Balance as of period end2011-12-3152.07M+29.4%2013-05-15Balance as of period end2010-12-3140.26M—2012-04-16Balance as of period endOther metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityCash & EquivalentsOperating Cash FlowCapital ExpendituresDividends Per ShareWeighted Average Diluted SharesEPS (Basic)